Description
ProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).
Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).
TransfectionReagentforDLD-1Cells(ColonCancerCells,CCL-221)
- Twocomponentformulationenhanceslipidmediatedtransfectionefficiency
- Optimizedeasy-to-usetransfectionprotocolprovidedfortransfectionofsiRNA,DNA,mRNA,andmiRNA
- KitincludesTransfectionEnhancerreagentandrecommendedtransfectionprotocol
- Hightransfectionefficacyinthe presenceofserum
- ExpandyourRNAiapplicationwithareagentoptimizedfordeliveryofbothsiRNAandplasmid
- ReproducIBLetransfectionresults
- Workswellforstandardreversetransfectionandhigh-throughputapplications
- DownloadinvitroDLD-1transfectionprotocol:[PDF]
- Download DLD-1CRISPR/Cas9transfectionprotocol:[PDF]
- DownloadPowerPointpresentationforDLD-1cellstransfectionkit:[PPT]
- DevelopedandmanufacturedbyAltogenBiosystems
TransfectionEfficiency:
Reagentexhibitsatleast86%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.
TransfectionProtocolandMSDS:
DownloadAltogenBiosystemsDLD1TransfectionProtocol:[PDF]
DownloadMSDS:[PDF]
DLD-1CellLine:
AspertheNationalCancerInstitute,colonandrectaladenocarcinomasarethethirdmostcommonlydetectedmalignanciesintheUnitedStates,withtheoverall5-yearsurvivalrateforadvancedstagepatientsbeingapproximately11%.Althoughcolorectaldeathratesaredecreasing,duetothedevelopmentofscreeningtestsenablingearlydetection,itcanbeespeciallychallengingtoincreasethesurvivalrateinpatientswithlate-stagecoloncancer.Celllinesareatthecoreofcancerresearch,andtheDLD-1colorectaladenocarcinomacelllineisoneofthemostcommonlyemployedcoloncancercelllines.Itiswellknownforitsabilitytogrowrapidly.TheDLD-1celllinewasestablishedin1979fromtheepithelialtumOrigenictissueofaDukes’typeCtumorofanadultmalepatientwithcolorectaladenocarcinoma.DLD-1ispositiveformyc,myb,ras,fos,sis,andp53oncogenesandnegativeforABL,ROS,andSRConcogenes.Thiscelllinecouldbeusedforresearchrelatedtocoloncancercells.DLD-1isofthesameclonaloriginascelllineHCT-15,makingthemsimilartoeachother.AltogenBiosystemsprovidespre-optimizedtwo-componenttransfectionreagentkitsfortheDLD-1coloncancercellline.Thesereagentshavedemonstratedhightransfectionefficiencywithreproducibleresults.
Data:
Figure1.GAPDmRNAlevelswerequantifiedusingreal-timeRT-PCRintheDLD-1cellstransfectedwithsiRNAstargetingGAPDornon-silencingsiRNA.Forty-eighthourspost-transfection,thecellswereharvestedandanalyzedbyreal-timeRT-PCRforGAPDmRNAexpressionlevels.Datawerenormalizedagainstthe18SrRNAsignal.Controlsampleswereeithermock-transfectedoruntreated.Valuesarenormalizedtountreatedsample.Dataaremeans±SD(n=5).
Figure2.ProteinexpressionofGAPDHinDLD-1cells.DNAplasmidexpressingGAPDHorsiRNAtargetingGAPDHweretransfectedintoDLD-1cellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.
DLD-1TransfectionReagent
AltogenBiosystems:
AltogenBiosystemsprovidespre-optimizedtransfectionkitsandelectroporationproductsforlifesciencesandcancerresearch.Transfectionprotocolsareoptimizedforindividualcancercelllines.AltogenBiosystemsdevelopedtwotypesofinvivodeliverykits(animaltransfection):1)Tissue-targetedreagents(deliveryofproteins,DNA,andRNAintoliver,pancreas,orkidneytissues),and2)Broadrangeinvivobiodistributionreagents(PEG-Liposomebasedreagent,Nanoparticle-basedinvivoreagent,Lipid-basedtransfectionkit,andPolymer-basedkit).Advancedformulationofreagentsandoptimizedtransfectionprotocolsprovideefficientintracellulardeliveryofproteins,DNA,mRNA,shRNA,siRNA,andothernegativelychargedbiomoleculesin vitroandinvivo.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.
AltogenLabsResearchServices:
AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BIOLOGyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).
VolumeOptions:
- 0.5ml(Catalog#6803)
- 1.5ml(Catalog#6804)
- 1.5mlCRISPR(Catalog#2139)
- 8.0ml(Catalog#7037)
